# Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

> **NCT02972333** · PHASE3 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 150 (estimated)

## Conditions studied

- EGFR-TKI Resistant Mutation
- Nonsmall Cell Lung Cancer
- AZD9291
- Brain Metastases

## Interventions

- **DRUG:** AZD9291 80mg oral each day
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT02972333
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2019-09
- **Final completion:** 2019-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2016-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02972333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02972333, "Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02972333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*